A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Items 401–500 of 638
Chiou, Y., Lin, P., & Lee, Y. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000079 · Cited by 4
Weidle, B., Ivarsson, T., Asbahr, F. R., Calvo, R. M., Mataix‐Cols, D., Rynn, M. A., & Storch, E. A. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113858 · Cited by 4
Bloch, M. H., Lennington, J. B., Szuhay, G., & Lombroso, P. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00106-6 · Cited by 5
Self-citationObsessive‐compulsive disorder: current management options
Harris, P. G., Drummond, L. M., & Fineberg, N. A. (2019) · Prescriber · doi:10.1002/psb.1793 · Cited by 5
Störungsorientierte Psychotherapie bei Zwangsstörungen
Poppe, C. (2008) · Elsevier eBooks · doi:10.1016/b978-343723730-0.50020-3 · Cited by 4
Paediatric OCD: Developmental Aspects and Treatment Considerations
GELLER, D. A., Faro, A. L., Brown, A. R., & Levy, H. C. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch7 · Cited by 5
Integrative Medicine Approach to Pediatric Obsessive-Compulsive Disorder and Anxiety: a Case Report
Couture, D. C., Chung, M. K., Shinnick, P., Curzon, J., Mcclure, M. J., & LaRiccia, P. J. (2016) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2015.091 · Cited by 4
“Over the course of 5 visits in a 5-month period, the patient was treated with the following: (1) a gluten-free diet and avoidance of gluten-containing personal care products such as soaps, shampoos, toothpaste, and hair products; (2) lowlevel laser ear acupuncture12-14 using a 904 nm laser RJ Olympic Physiolaser (RJ L…”
BackgroundMethodCompulsive hoarding associated with abortion.
Sockalingam, S., & Zemans, M. (2007) · PubMed Central · Cited by 4
Pharmacotherapy of Obsessive-Compulsive Disorder During Breastfeeding
Uğuz, F. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000500 · Cited by 4
“The augmentation with haloperidol was found to be effective in at least 2 meta-analyses despite being one placebo-controlled study.(52,53) Risperidone is an second-generation antipsychotics with the most consistent successful results supported by at least 4 meta-analyses.”
ResultCosta, D. L. D. C., Barbosa, V. S., Requena, G. D. L., Shavitt, R. G., Pereira, C. A. D. B., & Diniz, J. B. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117705087 · Cited by 4
Arnold, P. D., & Kronenberg, S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch60 · Cited by 4
Italian prescribing patterns in obsessive–compulsive disorder
Marazziti, D., Albert, U., Dell’Osso, B. M., Tundo, A., Cuniberti, F., Maina, G., Moroni, I., Benatti, B., Mucci, F., Massimetti, G., et al. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2641 · Cited by 4
“…unsuccessfully treated with SSRIs, practice guidelines suggest to add either one second‐generation antipsychotic (SGA), mainly risperidone or aripiprazole, or CBT/ERP [American Psychiatric Association, 2007; Bloch et al., 2006; National Collaborating Centre for Mental Health (Nice, UK), 2006].”
BackgroundEnglisch, S., & Zink, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-12952-5_11 · Cited by 5
Second-generation antipsychotic drugs for obsessive compulsive disorder
Komossa, K., Depping, A. M., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008141 · Cited by 4
Hollander, E., Poskar, S., & Gerard, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch6 · Cited by 4
Is there a Role for Immunological Mechanisms in Etiopathogenesis of Obsessive Compulsive Disorder?
Rao, N. P., Reddy, M. S. S., & Reddy, J. Y. C. (2013) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.112192 · Cited by 4
Verstraete, E., Dreesen, E., Schruers, K. R. J., Desplenter, S., & Bervoets, C. (2025) · ALPHA PSYCHIATRY · doi:10.31083/ap41734 · Cited by 3
“The one third of patients who do not respond adequately to 12 weeks of SSRI treatment, experience significant symptom improvement with antipsychotic augmentation [12].”
Ledwos, N., Baer, J., Husain, M. I., Blumberger, D. M., Patterson, R., Hollingdrake, E., Cheung, E. S. L., Hawco, C. S., Zrenner, C., Zrenner, B., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10895 · Cited by 4
Biological Mechanisms and Treatment of Obsessive–Compulsive Disorder
Pittenger, C. (2026) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081423-020516 · Cited by 6
Ziprasidone Augmentation in an Adolescent with Obsessive Compulsive Disorder: A Case Report
Demirkaya, S. K., & Alyanak, B. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4344 · Cited by 3
Medication Management of Childhood OCD
Ivarsson, T., Skarphéðinsson, G., & Weidle, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811427-8.00009-5 · Cited by 3
Cavanna, A. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816563-8.00003-6 · Cited by 4
Obsessive-Compulsive and Related Disorders
Pato, M. T., Arnold, P. D., Zohar, J., Bitan, S., Klein, K. P., & Eisen, J. L. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_23-1 · Cited by 3
Abdallah, S. B., Olfson, E., & Fernandez, T. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00011-x · Cited by 3
Goodwin, G. M., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., Binder, M. D., Falkai, P., Kapur, S., Leucht, S., Licht, R. W., et al. (2011) · Psiquiatría Biológica · doi:10.1016/j.psiq.2011.06.001 · Cited by 5
Obsessive-compulsive spectrum and suicidality in schizophrenia and mood disorders
Benvenuti, A., Rucci, P., Sbrana, A., Ravani, L., Massei, G. J., Gonnelli, C., & Cassano, G. B. (2009) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 3
Molecular imaging of obsessive–compulsive disorder
Figee, M., Booij, J., & Denys, D. A. J. P. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.019 · Cited by 3
Serotonin and Beyond: A Neurotransmitter Perspective of OCD
Abudy, A., Juven‐Wetzler, A., Sonnino, R., & Zohar, J. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch9 · Cited by 3
Evidence-Based Treatment Pathways for Translational Studies in Obsessive-Compulsive Disorders
Fineberg, N. A., Pallanti, S., & Reghunandanan, S. (2013) · Modern trends in psychiatry · doi:10.1159/000353618 · Cited by 3
Çocuk ve Gençlerde Aripiprazol Kullanımı: Olgu Serisi
Bildik, T., Özbaran, N. B., Küçükköse, M., & Ardıç, Ü. A. (2010) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.1080/10177833.2010.11790639 · Cited by 3
Gebelik ve Postpartum Dönemde Obsesif Kompulsif Bozukluk
Demirkol, M. E., Şimşek, L., Yılmaz, H., & Tamam, L. (2018) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.336626 · Cited by 4
Ahmadipour, E., Rashidi, F. S., Ahmadiani, A., Asadi, S., & Shams, J. (2018) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2018.10.001 · Cited by 5
Roessner, V., & Rothenberger, A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_27 · Cited by 3
Szechtman, H., Shivji, S., & Woody, E. Z. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_118 · Cited by 3
Sequential Allocation and Balancing Prognostic Factors in a Psychiatric Clinical TrialPreprint
Fossaluza, V., Diniz, J. B., Pereira, B. D. B., Miguel, E. C., & Pereira, C. A. D. B. (2008) · Nature Precedings · doi:10.1038/npre.2008.2102.1 · Cited by 4
“For second-line treatments, such as pharmacological augmentation strategies, the situation is worse, albeit understandably so (Bloch et al. 2006; Fontenelle et al. 2007).”
BackgroundMethod(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg005 · Cited by 3
Obsessive–Compulsive Disorders
Fineberg, N. A., & Padhi, A. K. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_323 · Cited by 3
Research on the Causes and Treatment of OCD
Wang, H. (2020) · Conference on Artificial Intelligence and Healthcare (CAIH) · doi:10.1145/3433996.3434030 · Cited by 2
Neurodevelopmental Disorders and Psychosocial Issues Later in Life
Zoccante, L., Antolini, G., Passarella, L., Puttini, E., Rizzo, V., & Colizzi, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-97906-5_7 · Cited by 2
Anxiety Disorders Are Associated With Greater Tic Severity in Youth With Chronic Tic Disorder
Sapozhnikov, Y., Mink, J. W., Adams, H., Walsh, N., Ross, A., Esposito, E. C., Oakes, L. A., & Vermilion, J. A. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.02.004 · Cited by 2
Marmureanu, M., Besoiu, M. V., Dionisie, V., Manea, M. C., Pleșea-Condratovici, C., Voican, S. I., & Manea, M. (2026) · Pharmaceuticals · doi:10.3390/ph19040628 · Cited by 2
“Its clinical utility is further constrained by tolerability issues, such as metabolic and extrapyramidal side effects [2,3].”
Neurodevelopmental Disorders: Motor Disorders
Vitulano, L. A., Vitulano, M. L., King, R. A., & Leckman, J. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch47 · Cited by 3
Self-citationNguyen, M. L., Shapiro, M. A., & Welch, S. J. (2012) · Journal of Behavioral Addictions · doi:10.1556/jba.1.2012.2.6 · Cited by 2
“However, these treatments usually take several weeks to achieve full effect (Bloch et al., 2006).”
BackgroundAufsuchende psychiatrisch- psychotherapeutische Versorgung
Stengler, K., & Jahn, I. (2020) · NeuroTransmitter · doi:10.1007/s15016-020-7403-3 · Cited by 2
“Obgleich es evidenzbasierte und in der Versorgung gut etablierte pharmakologische und psychotherapeutische Behandlungsstrategien bei Zwangsstörungen gibt [4], profitieren bis zu 60 % der Patienten von keiner der beiden oder einer kombinierten Therapie [5] und gelten damit als therapieresistent.”
BackgroundObsessive-Compulsive Symptoms in Schizophrenia
Poyurovsky, M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190228163.003.0057 · Cited by 4
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_4 · Cited by 3
Tümkaya, S., Yücens, B., Gündüz, M., Maheu, M., & Berkovitch, L. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niaf029 · Cited by 2
Bellia, F., Girone, N., Benatti, B., Vismara, M. E. M., Pettorruso, M., Martinotti, G., Dell’Osso, B. M., D’Addario, C., & Pucci, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188811 · Cited by 2
“For non-responding patients, antipsychotics are often prescribed alongside cognitive behavioral therapy (CBT) [12,13].”
Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch5 · Cited by 2
Pharmacological Treatment for Phobias and Anxiety Disorders
Bloch, M. H., & Mcguire, J. F. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7784-7_23 · Cited by 2
Self-citationDucasse, D., & Fond, G. B. (2013) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2013.09.001 · Cited by 2
Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy
Sayyah, M., Majzoob, S., & Sayyah, M. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.783011 · Cited by 3
“Arrival of the second-generation atypical antipsychotics with low risk of neurological adverse effects, in conjunction with the largest body of evidence in support of efficacy of lowdose atypical antipsychotics with an SSRI monotherapy in resistant cases of OCD, resulted in recommendation of antipsychotic augmentation…”
ResultLátalová, K., Kamarádová, D., & Praško, J. P. (2010) · Cited by 2
Psychopharmacology of Pediatric Anxiety Disorders
Mohatt, J. W., Keller, A. E., & Walkup, J. T. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6599-7_14 · Cited by 2
“At least nine double-blind placebo-controlled trials of antipsychotic augmentation of SSRIs exist in the adult OCD literature, all of which demonstrated signi fi cant effect [ 40 ] .”
BackgroundInternet Gaming Disorder Treatment Options in the Hospital Setting
Park, J. H., Hyun, G. J., Son, J. H., & Lee, Y. S. (2015) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.2015.26.2.75 · Cited by 2
Albert, U., Barbaro, F., Aguglia, A., Maina, G., & Bogetto, F. (2016) · Cited by 2
Vloet, T. D., Herpertz‐Dahlmann, B., & Simons, M. (2016) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000445 · Cited by 5
Screening for Schizophrenia in Recruits, Active Duty Soldiers and Veterans: Can we do a Better Job?
Detweiler, M. B., Chudhary, A. S., & Murphy, P. F. (2017) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000251 · Cited by 2
Singer, P., & Yee, B. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-53126-7_28 · Cited by 3
Treatment-Resistant Obsessive-Compulsive Disorder (OCD): Focus on Antipsychotic Augmentation to SRIs
Albert, U., Cori, D. D., Bogetto, F., & Maina, G. (2014) · ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) · Cited by 4
Could Dietary Glutamate be Contributing to the Symptoms of Obsessive-Compulsive Disorder?
Holton, K. F., & Cotter, E. W. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0105 · Cited by 2
Cognitive-Behavioral Therapy of Obsessive-Compulsive Disorder in Children and Adolescents
Çimen, İ. D. (2018) · InTech eBooks · doi:10.5772/intechopen.70612 · Cited by 2
“In augmentation strategy especially clomipramine and the atypical antipsychotics are commonly used [107, 108].”
BackgroundÖzen, M. E., Kalenderoğlu, A., Çelik, M., Örüm, M. H., & Hocaoğlu, Ç. (2019) · Adıyaman Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30569/adiyamansaglik.477617 · Cited by 5
Shafti, S. S., & Kaviani, H. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1597584 · Cited by 3
“OCD have only shown efficacy in placebo-controlled trials in single-site, small pilot trials [38].”
MethodPhenomenology and Standard Care of OCD in Children and Adolescents
Greenberg, E., & GELLER, D. A. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108235655.014 · Cited by 3
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_4-1 · Cited by 2
Modelos experimentais para o estudo do transtorno obsessivo compulsivo: perspectivas e limitações
Raminelli, A. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2021.tde-10052021-142439 · Cited by 4
Klimkeit, E., Rinehart, N., May, T., Whelan, M., & Bradshaw, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00082-x · Cited by 1
Obsessive-Compulsive Disorder: Strategies for Optimal Treatment
Hollander, E., Abramowitz, J. S., Koran, L. M., & Pallanti, S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1015 · Cited by 1
Shafti, S. S., & Kaviani, H. (2019) · Current Psychopharmacologye · doi:10.2174/2211556008666190314113446 · Cited by 3
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Pöppel, S., Ziegler, S., Bednasch, K., Kohls, E., & Rummel‐Kluge, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1642622 · Cited by 2
“Previous research has shown that antipsychotic augmentation (e.g., quetiapine, risperidone, or aripiprazole) may improve treatment outcomes in OCD that is refractory to treatment (29 – 32).”
A szkizoobszesszív zavarról két betegünk kapcsán
Csulak, T., Tényi, T., & Herold, R. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33377 · Cited by 2
Balachander, S., Bakam, A., Chakraborty, S., Shidore, M., Singh, N. A., Tholasappa, V., Vijayakumar, H. G., Sharma, L. P., Sharma, E., Reddy, Y. C. J., et al. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2605084 · Cited by 1
“In line with this, those with comorbid tics respond better to antipsychotic augmentation [22,37,38].”
Beneath the tip of the iceberg: treatment of neuropsychiatric comorbidities in tic disorders
Abi‐Jaoude, E., Gorman, D. A., & Sandor, P. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-13554-5.00008-0 · Cited by 1
Shahtou, A., Omara, H. R., Qari, S. A., Alqahtani, R. S., Alnasyan, Z. S., Alotaibi, A. E., Ali, A. A., Alabdulrahim, J. M., Naser, S. A., Asad, N., et al. (2026) · Cureus · doi:10.7759/cureus.108358 · Cited by 1
“Epidemiological and clinical trial data indicate that 40% to 60% of patients with OCD exhibit an inadequate response to optimal trials of SSRI monotherapy [9-11].”
Özsoy, F., Tasci, G., Taşçı, B., Doğan, Ş., & Tuncer, T. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.118161 · Cited by 1
Antipsychotic-drug-induced obsessive–compulsive symptoms
Poyurovsky, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511686931.014 · Cited by 1
Dell’Osso, B. M. (2007) · Evidence-Based Mental Health · doi:10.1136/ebmh.10.1.24 · Cited by 1
N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Fritzen, F., & Bloch, M. H. (2014) · Current Psychiatry Reviews · doi:10.2174/1573400510666140807005327 · Cited by 1
“Only 1 in 5 OCD patients will respond to antipsychotic augmentation that would not respond to SRI monotherapy [37].”
BackgroundSelf-citationAripiprazol: farmacología, eficacia clínica, seguridad y tolerabilidad en el adulto.
Belloso, F. J. D., & Loza, A. S. (2011) · Psiquiatria.com · Cited by 1
Trichotillomania and other impulse control disorders
Bloch, M. H. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511973796.016 · Cited by 2
Self-citationObsessive‐Compulsive Disorder: Assessment and Treatment
Abramovitch, A., Elliott, C. M., Wilhelm, S., Steketee, G. S., & Wilson, A. C. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch51 · Cited by 1
Optimal management of pediatric obsessive-compulsive disorder
Storch, E. A., Ung, & Ale (2012) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s23308 · Cited by 2
Augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder
Goddard, A. W., & Shin, Y. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511973796.005 · Cited by 1
Neurobiologie der Zwangsstörung: Teil 2: Konzepte und Befunde aus der Neurobildgebung
Hohagen, F., Kordon, A., & Zurowski, B. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1627159 · Cited by 1
The Compulsive-Impulsive Spectrum and Behavioral Addictions
Stein, D. J., & Harvey, B. A. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780195389715.013.0028 · Cited by 1
Tic & Tourette Syndrome and Motor Disorders
Park, T. W., & Park, J. (2016) · Hanyang Medical Reviews · doi:10.7599/hmr.2016.36.1.46 · Cited by 2
“For those who are less responsive to SRI, reinforcement using low dosage anti-dopaminergic agents such as risperidone can be effective [38].”
BackgroundChallenges in Managing Treatment-Refractory Obsessive-Compulsive Disorder and Tourette's Syndrome
Lizano, P. L., Popat-Jain, A., Scharf, J. M., Berman, N. C., Widge, A. S., Dougherty, D. D., & Eskandar, E. N. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000121 · Cited by 1
“This combination is consistent with results from controlled clinical trials indicating that OCD with tics is more refractory to SSRI therapy than OCD without tics, and often requires neuroleptic augmentation, with the best data currently indicating risperidone.(27) For OCD alone, while fluvoxamine is often cited as th…”
ResultObsessive–compulsive symptoms in schizophrenia: prodrome
Poyurovsky, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511686931.007 · Cited by 1
OCD, Anxiety Disorders, and PTSD
D’Urso, G., Sassi, T., de Bartolomeis, A., & Mantovani, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-33967-2_15 · Cited by 1
Poleszczyk, A., & Antosik-Wójcińska, A. Z. (2015) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr/60386 · Cited by 1
Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen
Volz, H. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_8 · Cited by 1
Sayyah, M., & Rahim, F. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i1.14528 · Cited by 2
“The latest available systematic reviews on antipsychotic therapies in resistant OCD are done from 2005 to 2006 [22,23]; thus, many new relevant researches have been published, an update of the current available literature seems necessary.”
BackgroundComorbidity in Obsessive‐Compulsive and Related Disorders
Frydman, I., Vigne, P., Ferreira, G. M., Campos‐Lima, A. L., Fontenelle, L. F., & de Menezes, G. B. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch63 · Cited by 1
Biological Models and Treatments for OCD in Adults
Stewart, S. E., & Loh, A. S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch14 · Cited by 1
Biological Models and Treatments for Obsessive‐Compulsive Related Disorders for Adults
Hudak, R., Borue, X., & Sharma, M. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch59 · Cited by 2
Relapse Prevention Strategies and Guidance on Refractory Cases
Selles, R. R., Jukes, T., McConnell, M., & Stewart, S. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811980-8.00016-9 · Cited by 1
Pharmacological Management of Tic Disorders in Youth
Saggu, B. M., Shad, S., Barnes, A. A., & Budman, C. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811980-8.00004-2 · Cited by 2
Sachdev, R. A., Ruparelia, R., Reid, J. E., Mpavenda, D., Cinosi, E., & Fineberg, N. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.016 · Cited by 2
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.